Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lacosamide
Drug ID BADD_D01238
Description Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focus of an epileptic seizure, as opposed to other antiepileptic drugs such as carbamazepine or lamotrigine which slow the recovery from inactivation and reduce the ability of neurons to fire action potentials.
Indications and Usage Lacosamide is indicated for adjunctive therapy for partial onset seizures in patients with epilepsy over 17 years old. Injection is indicated for short term use when oral therapy is not feasible.
Marketing Status Prescription
ATC Code N03AX18
DrugBank ID DB06218
KEGG ID D07299
MeSH ID D000078334
PubChem ID 219078
TTD Drug ID D05OFX
NDC Product Code 66689-108; 52038-005; 36998-1810; 27808-245; 50228-195; 69539-026; 36998-2477; 67877-733; 68462-678; 14445-012; 65977-0075; 14445-130; 50370-0024; 36998-2478; 68462-681; 65162-925; 47335-922; 69539-025; 0131-5410; 51991-349; 51991-350; 65162-924; 0131-1810; 62331-062; 69539-027; 51991-351; 36998-0119; 36998-2480; 65862-720; 66689-107; 50228-194; 27808-246; 31722-815; 0131-2479; 62332-172; 51991-348; 46708-860; 50228-192; 31722-814; 53296-0101; 0904-7247; 14445-129; 0904-7245; 68462-679; 66689-109; 50228-193; 36998-2479; 17205-107; 25021-791; 13612-0021; 65162-926; 62332-173; 0131-2477; 31722-812; 62332-171; 66651-914; 70166-617; 16436-0101; 67877-735; 14445-406; 14445-132; 66039-882; 67877-736; 0904-7246; 14445-021; 69539-028; 17180-2746; 27808-243; 62332-174; 67877-734; 31722-813; 47335-980; 65372-1186; 0131-2480; 47335-943; 66689-110; 0904-7244; 68225-057; 14445-131; 68462-680; 53747-069; 47335-918; 0131-2478; 27808-244; 12828-0087; 65162-923
Synonyms Lacosamide | Vimpat | N-benzyl-2-acetamido-3-methoxypropionamide | N benzyl 2 acetamido 3 methoxypropionamide | N-benzyl-AcMeOPrNH2 | N benzyl AcMeOPrNH2
Chemical Information
Molecular Formula C13H18N2O3
CAS Registry Number 175481-36-4
SMILES CC(=O)NC(COC)C(=O)NCC1=CC=CC=C1
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eczema23.03.04.0060.006704%
Electrocardiogram abnormal13.14.05.0010.010056%Not Available
Electrocardiogram QRS complex prolonged13.14.05.0030.020111%Not Available
Electrocardiogram QT prolonged13.14.05.0040.030167%
Electroencephalogram abnormal13.07.03.0010.006704%Not Available
Encephalopathy17.13.02.0010.020111%
Eosinophilia01.02.04.001--
Epilepsy17.12.03.0020.284911%Not Available
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Euphoric mood19.04.02.006--
Extravasation08.01.03.0080.006704%Not Available
Eye disorder06.08.03.001--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.0030.016759%
Facial bones fracture15.08.04.001; 12.04.05.0020.006704%Not Available
Fall12.01.08.002--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Feeling drunk08.01.09.015--Not Available
Feeling hot08.01.09.0090.006704%Not Available
Flatulence07.01.04.002--
Gait disturbance17.02.05.016; 08.01.02.0020.033519%
Gamma-glutamyltransferase increased13.03.01.0110.013408%
Gastric cancer16.13.03.001; 07.21.02.0010.001749%Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Generalised oedema14.05.06.007; 08.01.07.0040.006704%
Generalised tonic-clonic seizure17.12.01.0020.056982%Not Available
Hallucination19.10.02.0020.043575%
Hallucination, auditory19.10.02.0030.006704%Not Available
Headache17.14.01.001--
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 12 Pages